BioCryst Drug Boosted Existing Gout Treatment In Study - Wall Street Journal

BioCryst Drug Boosted Existing Gout Treatment In Study Wall Street Journal The study showed the combination of BCX4208 and gout-treatment allopurinol reduced serum uric acid concentration more than either drug alone. ... BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined ...MarketWatch (press release) BioCryst gout drug shows promise in mid-stage trialReuters BioCryst Pharma Reports Positive Results From Phase 2 Study Of Gout Drug - UpdateStock Markets Review Birmingham Business Journal all 27 news articles »

Savient's big gamble pays off with approval of gout drug - The Star-Ledger - NJ.com

TopNews United Kingdom (blog)

Savient's big gamble pays off with approval of gout drug The Star-Ledger - NJ.com At one point, driven by encouraging study data and high hopes, the company sold off a collection of other products to generate more cash to pay for its work ... FDA Approves KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in ...MarketWatch (press release) FDA Approves Pegloticase for Refractory GoutMedscape Savient shares rally as FDA approves gout drugReuters eMaxHealth -Arthritis Today all 199 news articles »

Nuon Therapeutics Announces Gout Program Study Results to Be Presented at the ... - Business Wire (press release)

Nuon Therapeutics Announces Gout Program Study Results to Be Presented at the ... Business Wire (press release) ... in phase 2b development for the treatment of hyperuricemia in patients with gout. Topline results from a completed proof-of-principle, phase 2a study, ... and more »

Doctor, doctor: Migraines and arthritis - The Guardian

The Guardian

Doctor, doctor: Migraines and arthritis The Guardian It might even be a sign of gout. You don't mention whether you have been to see a doctor – new arthritis in a single joint at any age needs to be checked up ...